Session: SAT 109-133-GHRH, GH & IGF Biology & Signaling
Bench to Bedside
Poster Board SAT-113
Objective. We investigate the relationship between use of proton pump inhibitors and IGF system in the elderly.
Subjects and Methods. Our series consisted of 938 older subjects (536 women, 402 men, mean age 75.7 ± 7.4 years) enrolled in the InCHIANTI study for which complete data on IGF-1, IGF-binding protein-1 and -3 (IGFBP-1, IGFBP-3) and medications were available. IGF-1, IGFBP-1 and IGFBP-3 were measured by immunoradiometric assay. Multivariate linear regression analysis adjusted for age, sex, BMI, liver function, number of drugs, caloric intake and IGFBP-1 and -3 was used to estimate the association between PPI use and IGF-1.
Results The mean age of whole population was 75.7 ± 7.4 years ± SD. Participants were categorized by PPI use, identifying 903 PPI non users and 35 PPI users. PPI users and non users differed by BMI, number of medications and IGF-1 levels. PPI users had lower IGF-1 levels than non-users. After adjusting for age, male PPI users (107.0±69.6 vs 127.1±55.8, p<0.001) and female PPI users (87.6±29.1 vs 107.6±52.3, p=0.03) had lower levels of IGF-1 than non users. IGFBP-1 levels were similar in 2 groups in both men and women. In whole population, after adjustment for age and sex. PPI users had lower IGF-1 levels 81.9 [61.1-113.8] than non users 110 [77.8-148.6], p=0.02.After further adjustment for BMI, liver function, number of drugs, caloric intake and IGFBP-1, the relationship between PPI use and IGF-1 was still negative and statistically significant (β±SE= -18.09±9.38, p=0.05).
Conclusions. Use of PPI is independently and negatively associated with IGF-1 levels, supporting the link between use of PPI and malnutrition observed in older subjects.
Nothing to Disclose: MM, CC, FL, FD, SB, GB, ES, MM, AC, FL, LF, GC
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters